Technology | May 07, 2014

FDA Clears GE’s Discovery IGS 740 Mobile Angiography System

System designed to meet needs of interventional radiology without limits of fixed-base systems

GE Healthcare Discovery IGS 740 Mobile Angiography System FDA Approval

May 7, 2014 — GE Healthcare received U.S. Food and Drug Administration (FDA) clearance for its Discovery IGS 740, a new rail-free mobile angiography system with a 41x41 cm detector. The Discovery IGS 740 is the first of this kind of mobile angiography system in the industry to receive FDA approval.

This new imaging system puts interventional radiologists at the center of their procedures. The rail-free design allows healthcare professionals ample access to the patient while freeing clinical teams from the constraints of fixed ceiling-mounted system rails. Its wide bore C-arm and dedicated arm-imaging positions create ease in imaging the anatomy of interest and full patient access from the left or right. A rotating laser continuously scans the room so the system knows where it is at all times.

By eliminating the ceiling rails, installation is simplified for flexibility in designing the room and positioning ceiling-mounted ancillaries (monitors, radshields, lights) where healthcare professionals need them.

The Discovery IGS 740 is equipped with two customizable parking positions to accommodate multiple room sizes and shapes. The 41x41-cm detector enables imaging of large organs, such as the liver and simultaneous coverage of both legs. The wide-bore C-arm helps interventional radiologists image large patients and conveniently perform off centered 3-D acquisitions. In addition, the system comes equipped with more than 20 advanced applications, such as FlightPlan for Liver, which helps clinicians identify tumor-feeding vessels in a few clicks, and be selective during liver embolizations.

For more information: newsroom.gehealthcare.com

Related Content

News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Overlay Init